Please try another search
By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Novo Nordisk raised its 2024 outlook on Thursday as the Danish drugmaker races to boost output of its Wegovy weight-loss treatment,...
By Ankika Biswas and Johann M Cherian (Reuters) -European shares fell slightly in their first May trading session on Thursday as investors returned from a mid-week holiday to gauge a slew of earnings...
By Ludwig Burger (Reuters) - Online pharmacies and slimming clinics are cutting prices for Wegovy and Mounjaro in Britain just months after the weight-loss drugs were launched there, as initial...
LONDON (Reuters) - Novo Nordisk (CSE:NOVOb) has seen the price of its hugely popular weight-loss drug Wegovy and diabetes drug Ozempic fall in the United States as volumes and competition have...
By Martin Coulter LONDON (Reuters) -Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk (CSE:NOVOb), said on Wednesday it planned to invest around $200 million in...
(Reuters) -Most doses of Eli Lilly (NYSE:LLY)'s diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand, the...
By Bhanvi Satija and Eva Mathews (Reuters) -The European Union drug regulator found no evidence that a class of diabetes and weight-loss drugs such as Novo Nordisk (CSE:NOVOb)'s hugely popular...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review